Navigation Links
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Date:5/11/2009

FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation," at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 3-7, 2009, in Fort Lauderdale, Florida. PF-04523655 is currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD).

The study presented at ARVO was performed in collaboration with Dr. Jayakrishna Ambati at the Department of Ophthalmology and Visual Sciences, University of Kentucky College of Medicine, Lexington, KY. The objective of the study was to determine whether PF-04523655, a synthetic chemically modified 19-bp siRNA, enters cells in the retina leading to downregulation of its target gene while avoiding activation of Toll Like Receptor 3 (TLR3). Previous studies from Dr. Ambati's laboratory have shown that unmodified 21-mer siRNA molecules exhibit antiangiogenic effects by inadvertently activating TLR3 rather than down-regulating expression of their target genes. Results obtained in vivo and in vitro indicated that PF-04523655 does enter cells in the retina and elicits its pharmacologic effect via target gene knock-down without activating TLR3.

Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "We believe that the results presented at ARVO continue to substantiate our leadership in siRNA therapeutics, in particular Quark's ability to develop highly specific siRNA products and advance them through the clinic toward commercialization. Quark's ability to establish col
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
4. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. ... company focused on advanced wound care, announces that ... tissues, have been added to the Premier, Inc. ... the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... The report provides basic information on ... and industry overview. This report also presents product ... is separated by regions, technology and applications. The ... client survey, marketing channels, industry development trend and ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 23, 2011 Novavax, Inc. (Nasdaq: NVAX ) ... results in a press release to be issued after 8:00 ... hold an investor conference call at 10:00 a.m. The call ... Dr. Rahul Singhvi and other members of senior management. The ...
... SA , a Swiss-based biotechnology company with technologies for ... stable mammalian cell lines for therapeutic ... sequencing of their proprietary Chinese hamster ovary (CHO) cell ... performed in collaboration with the Institute of Biotechnology ...
... MARLBOROUGH, Mass., March 23, 2011 Advanced Cell Technology, ... a leader in the field of regenerative medicine, announced ... allowed the Company,s patent application to provide broad intellectual ... preparations of retinal pigment epithelial (RPE) cells from human ...
Cached Biology Technology:Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 2Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 3Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 4ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
(Date:12/10/2014)... 08, 2014 Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... Market in Japan 2014-2018" report to their offering. ... The integration of biometrics and smart cards for projects ... license is one of the major trends witnessed in ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... this month's Vaccine 1 highlights the huge gap between ... by the European Union. Currently, only one third (35%) ... vaccine in Europe, resulting in avoidable morbidity, hospitalisations and ... have attempted to develop a model to enable European ...
... on parade, the cyclic tungsten trioxide clusters line up ... from each cluster is raised slightly, holding forth the ... constitute a new model system, a simplified version of ... Such models reveal to chemists the exact structure and ...
... rhinovirus (HRV), the leading cause of most common colds, ... respiratory failure, graft dysfunction and death. The two were ... suffered clinically significant respiratory infection from HRV in both ... that HRV affects only upper airway tissue. , The ...
Cached Biology News:First-time analysis reveals millions of Europeans left at risk from influenza 2First-time analysis reveals millions of Europeans left at risk from influenza 3Uniform tungsten trimers stand and deliver 2Common cold virus leads to death in lung transplant patients 2
...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Biology Products: